HEMOGENYX
HemoGenyx LLC, a privately held biopharmaceutical company, is developing a revolutionary new treatment for blood diseases, such as leukemia and lymphoma. They leverage a special class of cells, which can generate cancer-free blood stem cells. Their therapy will dramatically increase the efficacy of bone marrow transplants and eliminate the need for donors.
HEMOGENYX
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2013-01-01
Address:
Buffalo, New York, United States
Country:
United States
Website Url:
http://www.hemogenyx.com
Total Employee:
11+
Status:
Active
Contact:
+1 (347) 735-8380
Total Funding:
61.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Mint Capital
Mint Capital investment in Post-IPO Debt - HemoGenyx
43North
43North investment in Seed Round - HemoGenyx
Official Site Inspections
http://www.hemogenyx.com
- Host name: li677-21.members.linode.com
- IP address: 88.80.184.21
- Location: London United Kingdom
- Latitude: 51.5164
- Longitude: -0.093
- Timezone: Europe/London
- Postal: EC2V
More informations about "HemoGenyx"
About – Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals plc is registered in England and Wales as company number 08401609 at 6th Floor, 60 Gracechurch Street, London, EC3V 0HR, United Kingdom. LEI …See details»
Hemogenyx Pharmaceuticals – Breakthrough therapies for the …
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your …See details»
HemoGenyx - Crunchbase Company Profile & Funding
HemoGenyx LLC, a privately held biopharmaceutical company, is developing a revolutionary new treatment for blood diseases, such as leukemia and …See details»
Capital re-organisation and new ISIN – Hemogenyx Pharmaceuticals
Dec 10, 2024 Hemogenyx Pharmaceuticals Announces The Approval of its Proposed Capital Reorganisation and New ISIN. Hemogenyx Pharmaceuticals plc (LSE: HEMO), the …See details»
Hemogenyx Pharmaceuticals Company Description - Stock Analysis
Dec 24, 2024 Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for …See details»
HemoGenyx - businessabc
Dec 18, 2024 HemoGenyx is committed to translating novel technologies into safe, effective and affordable therapies for patients with rare hematological diseases. Vision HemoGenyx’s vision …See details»
HemoGenyx Pharmaceuticals Plc (HemoGenyx Pharmaceuticals …
Enquiries: Hemogenyx Pharmaceuticals plc Dr Vladislav Sandler, Chief Executive Officer & Co-Founder [email protected] Peter Redmond, Director …See details»
Hemogenyx Pharmaceuticals Plc - AnnualReports.com
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company is developing products for bone …See details»
Hemogenyx Pharmaceuticals LLC Details - govtribe.com
Oct 14, 2024 Federal Vendor Profile for Hemogenyx Pharmaceuticals LLC. GovTribe All Vendors Help . Hemogenyx Pharmaceuticals LLC UEI RWVGAMWRK6S1. Division …See details»
Hemogenyx Pharmaceuticals - Org Chart, Teams, Culture & Jobs
Hemogenyx Pharmaceuticals plc is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative …See details»
HemoGenyx - Funding, Financials, Valuation & Investors
Organization. HemoGenyx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Stock Symbol LSE:HEMO. Funding Rounds …See details»
HemoGenyx - Contacts, Employees, Board Members, Advisors
Organization. HemoGenyx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of Board …See details»
HemoGenyx Company Profile: Overview and Full News Analysis
Shares of UK drug developer Hemogenyx Pharmaceuticals (LSE: HEMO) rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail …See details»
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment …
Oct 2, 2024 Prevail Partners, LLC to invest again in Hemogenyx Pharmaceuticals Prevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric …See details»
Operations Update – Hemogenyx Pharmaceuticals
The Company continues to work with Prevail Infoworks, a contract research organization ... Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in …See details»
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment …
Oct 2, 2024 Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals …See details»
HEMO - Hemogenyx Pharmaceuticals PLC Key Metrics - Morningstar
5 days ago Review the current Hemogenyx Pharmaceuticals PLC (HEMO:XLON) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if HEMO is the …See details»
Hemogenyx Pharmaceuticals Stock Price - Markets Insider
Dec 20, 2024 HemoGenyx Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of a suite of products to …See details»
Hemogenyx Pharmaceuticals Announces Strategic Investment …
Sep 18, 2023 Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals. ... (“MSTA”) with Prevail InfoWorks, Inc. (“InfoWorks”), a Philadelphia, PA based Contract Research …See details»
Hemogenyx Pharmaceuticals PLC Announces CBR Macrophage …
Dec 6, 2024 LONDON, UK / ACCESSWIRE / December 6, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical company, is pleased to announce a …See details»